PORTLAND, Ore.--(BUSINESS WIRE)--HemCon Medical Technologies, Inc., announced the appointment of Nick Hart as President, effective today.
Following HemCon's acquisition of Alltracel Pharmaceuticals in 2008, Mr. Hart has served as the Company's Chief Financial Officer. Hart has over 20 years of financial experience in the life sciences sector.
"Nick is not only a skilled Chief Financial Officer, but has the leadership and strategic vision required to move into the role of President to lead HemCon as it prepares to introduce new products in the US and internationally over the next twelve months. We are pleased to announce his appointment. Nick has the full confidence of the Board and signifies a new era of management," said William P. Wiesmann, M.D., Chairman of the Board. "Nick's international experience and business skills will be increasingly important as HemCon enters into these new markets and product launches."
"I am honored to lead the HemCon team. I welcome this opportunity and look forward to growing the Company," stated Hart.
Mr. Hart replaces John W. Morgan, who resigned as of today to pursue other opportunities. Mr. Morgan served as President and Chief Executive Officer since 2004.
Dr. Wiesmann praised Mr. Morgan's work for HemCon. "John has done an excellent job leading the Company. He oversaw equity funding, helped the Company obtain significant government grants to develop life-saving technologies, and negotiated an international acquisition that expanded HemCon's access to new technologies and operations in Europe and opened new markets for the Company's products. We wish him success in his future endeavors," said Wiesmann.
HemCon Medical Technologies, Inc. (www.hemcon.com), founded in 2001, develops, manufactures, and markets innovative technologies to control bleeding and infection resulting from trauma or surgery. HemCon products are designed for use by military and civilian first responders as well as medical professionals in hospital, dental and clinical settings where rapid control of bleeding is of critical importance. In addition, HemCon is leading the charge to develop and license unique, life-saving medical advances including lyophilized human plasma. HemCon is headquartered in Portland, Ore., with additional commercial operations in Ireland and the Czech Republic.